This stable HepG2 transfectant developed in our laboratory and termed as HepR21 displayed cell proliferation by upregulation of cyclin D1 in an AKT-dependent pathway, instead of growth retardation; all leading to increased tumor potency [32]. This evidence concerns the gene AKT1 and neoplasm.